openPR Logo
Press release

Kaposi Sarcoma Market : Precise Analysis on Business Overview, Product Scope And Ongoing Market Development 2016 - 2024

07-10-2018 11:32 AM CET | Health & Medicine

Press release from: Transparency Market Research 

Kaposi Sarcoma Market : Precise Analysis on Business Overview,

The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of several major drugs.

Partnerships, acquisitions, and collaborations with other leading companies for the development of newer products with improved efficacy are part of the growth strategies adopted by a number of players in the Kaposi sarcoma market. For instance, F. Hoffmann-La Roche Ltd launched a new Global Access Program in September 2014 in partnership with the Joint United Nations Program on HIV/AIDS, the President’s Emergency Plan for AIDS Relief, the Clinton Health Access Initiative, and the Global Fund. The program was centered on HIV viral load testing.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3354

High Incidence of HIV/AIDS, Organ Transplants Driving Growth of KS Market

Increased organ transplant procedures are a leading factor driving the Kaposi sarcoma market since the incidence of the cancer is high among patients who have undergone an organ transplant. “Organ transplant patients are given immunosuppressive agents to prevent their body from rejecting the graft. This makes them highly susceptible to Kaposi sarcoma associated herpesvirus (KSHV) infection,” the author of the study explains. The long term use of these agents increases the rate of risk of these patients by more than 100 times compared to the general population.

The high incidence of HIV/AIDS associated Kaposi sarcoma is one of the major factors driving the adoption of HAART therapy, which subsequently fuels the overall KS market.

High Cost of Treatment a Major Drawback

The cost of cancer drugs used for the treatment of Kaposi sarcoma has been on the rise in the past few years, making it difficult for patients to seek treatment. This is a major concern for both the patients and the payers. “The prices of patented drugs have increased by over five times in the past few years in the U.S. and continue to rise,” the TMR analyst comments. For instance, prices of major drugs used for the treatment of KS, such as liposomal doxorubicin, liposomal daunorubicin, or paclitaxel in combination with HAART, have been increasing significantly, making these unaffordable for middle and lower income groups.

Slow but Steady Growth in Store for Kaposi Sarcoma Market

The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in the KS market, expanding at a 2.6% CAGR from 2016 to 2024.

Enquiry for Discount on this Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=3354

By type of treatment, HAART led the overall Kaposi sarcoma market in terms of revenue, with chemotherapy and immunotherapy poised to register the highest growth rate over the coming years. In terms of region, the global Kaposi sarcoma market was led by North America in 2015 and the MEA region will record the fastest growth by 2024.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email:sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Kaposi Sarcoma Market : Precise Analysis on Business Overview, Product Scope And Ongoing Market Development 2016 - 2024 here

News-ID: 1117554 • Views:

More Releases from Transparency Market Research 

Oligonucleotide Therapeutics Market Size, Status, Scope and Growth Prospects 2020-2030
Oligonucleotide Therapeutics Market Size, Status, Scope and Growth Prospects 202 …
Global Oligonucleotide Therapeutics Market: Overview Oligonucleotides refer to short chain DNA or RNA that are generally made by using automated synthesizers. In addition, purification of oligonucleotide is accomplished by anion exchange chromatography and it is followed by the techniques of freezing and desalting. In addition, synthesis of siRNA duplex oligonucleotide is done through an annealing step in which two purified strands of oligonucleotide are brought closer together in an equimolar ratio.
Seasonal Affective Disorder Therapeutics Market Size, Status, Scope and Growth Prospects 2020-2030
Seasonal Affective Disorder Therapeutics Market Size, Status, Scope and Growth P …
Global Seasonal Affective Disorder Therapeutics Market: Overview From 2020 to 2030, the global seasonal affective disorder is set to witness new profitable avenues. It is set to chart growth at a sturdy rate, compounded annually, with massive contributions coming from the North American region. On the other hand, Asia Pacific is anticipated to grow at an impressive CAGR. Transparency Market Research notes that various factors are contributing towards the projected growth. These
Esthetic Lasers and Energy Devices Market set to witness surge in demand over the forecast period of 2017 - 2025
Esthetic Lasers and Energy Devices Market set to witness surge in demand over th …
In the past few years, the cosmetic industry has found new bioactive and high potency ingredients, which offer noticeable skin benefits to consumers. Various technological advancements in the esthetic industry, increase in disposable income, surge in awareness about skin rejuvenation & appearance are the major factors driving demand for esthetic procedures in developed as well as developing markets. The trend of adoption of innovative and advanced surgical devices in the
Image Guided Surgery Devices Market Analysis and Research Report by Experts 2025
Image Guided Surgery Devices Market Analysis and Research Report by Experts 2025
The global image guided surgery devices market is directly reliant on the development of healthcare across various regional longitudes of the world. As the healthcare industry make rapid advancements across a number of its sub-domains, the market for global image guided surgery devices would see the entry of new players into the market. The competition is expected to intensify in the coming years and wreak the need for proper strategizing

All 5 Releases


More Releases for Kaposi

Kaposi Sarcoma Treatment Market Drivers
Increasing number of patients undergoing organ transplant procedures is the leading cause for growth of the Kaposi sarcoma treatment market, as patients undergoing organ transplants are highly susceptible to this cancer. For instance, according to the National Kidney Foundation (NKF), in 2014, 17,107 kidney transplants took place in the U.S. Among which, 11,570 came from deceased donors and 5,537 came from living donors. Furthermore, increasing incidence of HIV/AIDS-associated Kaposi sarcoma
Kaposi Sarcoma Treatment Market Competitive Landscape
Kaposi sarcoma is a malignant tumor disease majorly associated with skin, mucous membranes, lymph nodes, and other organs. Kaposi sarcoma causes lesions to grow in the skin, in the mucous membranes lining the mouth, nose, and throat, lymph nodes, and other organs. Human herpesvirus-8 (HHV-8) is majorly found in the lesion of all patients suffering from Kaposi sarcoma. However, patients with weakened immune systems by Acquired Immune Deficiency Syndrome (AIDS)
Kaposi Sarcoma Market: High incidence of HIV/AIDS associated Kaposi sarcoma is o …
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of
Kaposi Sarcoma Market Analysis & Trends 2024
The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in
Kaposi Sarcoma Market Research Report 2024
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of
04-04-2017 | Health & Medicine
TMR
Kaposi Sarcoma Market: Patent Expiry of Blockbuster Drugs for Treatment of Kapos …
Kaposi sarcoma is a soft tissue sarcoma that develops in connective tissues, blood vessels, fibrous tissues, and muscles. It is a malignant, multi-centric, neoplastic vascular proliferation, characterized by the development of bluish-red cutaneous nodules on the feet. According to the U.S. Center for Disease Control and Prevention (CDC), Kaposi sarcoma is considered an acquired immune deficiency syndrome (AIDS) defining disease. This report analyzes the current and future prospects of the